Ms. Angela Riemer serves as Vice President, Global Policy and Public Affairs, Oncology for Pfizer, one of the world’s largest research-driven health care products  companies. Before assuming her current role, Angela led Pfizer’s Federal Government Relations team.  Angela began health policy work at Medco Health Solutions as a director in that company’s government affairs division. She joined Medco after serving as Executive Director of the Congressional Black Caucus Political Action Committee (CBC PAC). Before that, Angela was marketing manager for start-up community development bank City First Bank of D.C. She started her career at Prudential Financial where she became a director in government affairs.

Angela is a member of the Silver Spring (MD) chapter of The Links Incorporated and the Montgomery County, Maryland Chapter of Jack and Jill of America, Inc. She also serves on the Board of Directors of the Public Affairs Council.  Angela is a graduate of Princeton University. She lives in Takoma Park, Maryland with her husband Hans Riemer and their two sons.

Phillip Davis, MD, is a nuclear medicine physician based in Charleston, South Carolina who has been employed full-time by Blue Earth Diagnostics (BED) since May 2019. Prior to joining the development and medical teams at BED, Dr. Davis spent 10 years working in the division of medical imaging and radiation medicine at the FDA in Silver Spring, Maryland. He recently served as the medical lead on the phase 3 trials of POSLUMA in the US, which culminated in our approval on May 25, 2023.

June M. Chan, Sc.D. is a Professor and Vice Chair for Education in the Department of Epidemiology & Biostatistics and she is also a Steven & Christine Burd-Safeway Distinguished Professor in the Department of Urology at the University of California, San Francisco. Professor Chan is a cancer epidemiologist, and her research focus includes health behaviors (e.g., diet, exercise, screening), social determinants, and cancer survivorship; understanding the biological effects of health behaviors on prostate cancer outcomes; and circulating and tissue biomarkers for prostate cancer prognosis.

Barney Morris is a member of Moffitt Cancer Center’s Patient and Family
Advisory Council and Community Advisory Board. He is the current vice
chairman for Oncology Research Information Exchange Network’s (ORIEN)
Patient Advisory Council where as a cancer survivor and advocate he frequently
uses his public speaking skills and real life experiences to bring home the
importance of being purposeful and intentional in eliminating health care
disparities and inequities particularly as it relates to prostate cancer.

He is the Past President of 100 Black Men of Tampa Bay Inc’s chapter and
Chair of their Health and Wellness committee. Barney is an alumnus of the
University of Georgia (Bachelor of Science in Computer Science), University of
California Riverside ( Certificate in Governmental Accounting and Budgeting),
Air Force Squadron Officer School and Air Force Air Command and Staff
College. He’s a decorated retired Air Force Officer, (Major), having served a
combined total of twenty years between active and reserve forces. Barney
recently retired as an Assistant Inspector in Charge, United States Postal
Inspection Service where he was responsible for the investigative efforts in
Georgia and Florida.

More recently Barney joined the Prostate Health Education Network, PHEN, as
a PHEN Ambassador.

Dr. Daneil Kuftinec joined Lantheus in March 2022 from Lahey Hospital and Medical Center in Burlington, Massachusetts where she served as a board-certified Urologist in clinical practice for 15 years. She is member of the American Urological Association.

She received her medical degree from Tufts University. Dr. Kuftinec completed residencies at Boston University and its affiliated Boston Medical Center, Boston Children’s, and VA Boston Healthcare hospitals

Daneil lives in Carlisle , Massachusetts with her husband and two sons.

Jennifer Phillips, PhD, is a seasoned oncology leader with expertise in prostate cancer and a strong commitment to patient-centered care.   As Group Medical Director at J&J Innovative Medicine, she leads strategic initiatives that bridge clinical research, medical affairs, and patient advocacy. Her work focuses on advancing therapeutic innovation, improving patient outcomes, and fostering inclusive engagement across diverse communities.

Jennifer has actively participated in national forums where she has contributed to discussions on genetic testing, patient education, and health equity.

She collaborates closely with advocacy groups, professional societies and academic institutions to promote precision medicine and ensure that patient voices are central to clinical development and communication strategies.

She has a PhD in pharmacology from the University of Pennsylvania and has been involved in drug development including the approvals of Promacta, Arzerra, and Balversa.

Her personal journey, including the loss of both her grandfather and uncle to prostate cancer and her sister to colorectal cancer, fuels her passion for advancing oncology care and amplifying the impact of patient advocacy.

Jennifer’s leadership continues to shape meaningful partnerships and drive forward the mission of access and informed decision-making in prostate cancer treatment.